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INTRODUCTION
Colorectal cancer (CRC) and inflammatory bowel
disease (IBD) are a quite common colon disease in
the world.1,2 There is a trend in increased incidence
rate of such disease in developing countries, including
Indonesia. A study by Murdani demonstrates that
38.77% CRC in Indonesia is found in patients under
40 years of age.3 The World Gastroenterology
Organization (WGO) suggest screening tests for
detecting CRC, i.e. the fecal occult blood test (FOBT)
and colonoscopy.1-3 CRC is one of important and
significant factors in high morbidity and mortality rate
in the United States of America and the world. CRC
is a worldwide problem; with an annual incidence of
approximately one million cases and an annual
mortality rate more than 500,000 cases. Most CRC
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Diagnosis of CRC is established based on a good history taking, clinical manifestation, physical
examination and laboratory examination. Other supporting laboratory tests include routine laboratory
test of hemoglobin for detecting anemia, examination of bleeding stool either macroscopically or
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6 cascades, which depend on the risk of colorectal cancer and local facilities available.
There are several kinds of FOBT, but the most frequently used include three methods, i.e.: the FOBT
guaiac base/traditional, the fecal immunochemical test (FIT) and the FOB + transferrin rapid test
(OT 102c & OT 103c).  FIT and FOB + transferrin rapid test have a quite high sensitivity and specificity
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arise from sporadic adenomas, and a few from
genetic polyposis syndrome or IBD.1,2
COLORECTAL CANCER
Diagnosis
Diagnosis of CRC is established based on a good
history taking, clinical manifestation, physical
examination and laboratory examination. Questions
about clinical manifestations that should be asked on
history taking include change in defecation pattern –
sometimes watery or hard stool, bleeding stool
(hematochezia), weight loss, and pallor on the skin and
body due to blood loss. The physical examination
demonstrates pallor on skin and conjunctiva, weight
loss and thin body indicating malnutrition.
At the advanced stage, abdominal tumor mass may be
found. Some laboratory tests are necessary, i.e.
routine laboratory test of hemoglobin for detecting
anemia, examination of bleeding stool either
macroscopically or microscopically. Abdominal ultra-
sonography may reveal tumor mass/colon cancer,
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the occurrence of metastases to the liver and adjacent
abdominal organ. Radiographic examination, either
colon in loop or colonoscopy (if such modalities are
available), shall be performed to confirm the
occurrence of cancer mass in the colon. Moreover,
biopsy examination is carried out to obtain the
histopathological feature of tumor mass or the type of
cancers. The CT-scan or abdominal magnetic
resonance imaging (MRI) is intended to confirm
the diagnosis of CRC and metastases; while the chest
X-ray confirmed the lung metastases.1,3
Screening
WGO has made a guideline for CRC screening,
which consists of 6 cascades, which depend on
the risk of CRC and local facilities available.1
• Cascade level 1
The cascade recommendation is appropriate for
countries with a relatively high level of resources
(financial, professional, facilities) and where
the CRC mortality is high (The International
Agency for Research on Cancer Data) and it
becomes an important concern to public health
priorities. Colonoscopy recommendation for
average-risk male and female starts at the age of
50 and every 10 years in the absence of factors
that would place them at increased risk.
Recommendation for screening people at
increased risk is applied for: people with a family
history of CRC or adenomatous polyps; people
with a first-degree relative (parent, sibling, or
child) with colon cancer or adenomatous polyps
diagnosed under the age of 60; or people with
two first-degree relatives diagnosed with CRC at
any age should be advised to have screening
colonoscopy starting at the age of 40 or 10 years
younger than the earliest diagnosis in their
family, whichever comes first and repeated
every 5 years; people with a first-degree relative
with a colon cancer or adenomatous polyp
diagnosed when he/she was over the age of 60;
or with the second-degree relative with CRC
should be advised for screening as the average-
risk people, but starting at the age of 40; people
with second-degree relative (grandparents, aunt
or uncle) or third-degree relative (greatgrand-
parent or cousin) with CRC should be advised
for screening as the average-risk people.
Familial adenomatous polyposis (FAP). People
who have a genetic diagnosis of FAP, or people
who are at risk of having FAP but in whom
genetic testing has not been performed or is not
feasible, should have an annual sigmoidoscopy
beginning at age of 10-12, to determine whether
they are expressing the genetic abnormality.
Genetic testing should be considered in patients
with FAP who have relatives at risk. Genetic
counseling should precede the genetic testing and
consideration of colostomy.
Hereditary nonpolyposis colorectal cancer
(HNPCC). People with a genetic or clinical
diagnosis of HNPCC or people who are at
increased risk for HNPCC, should have
colonoscopy every 1-2 years, starting at the age
of 20-25 or 10 years earlier than the youngest
age of colon cancer diagnosis in the family, which-
ever comes first. The genetic testing for HNPCC
should be offered to first-degree relatives with a
known inherited mismatch repair (MMR).
It should also be offered when the family
mutation is not already known, but one of the three
modified Bethesda criteria is met.
People with a history of IBD or adenomatous
polyp or CRC are candidates for follow-up
surveillance, rather than screening. Guidelines
have been published for the surveillance of these
individuals.
• Cascade level 2
The recommendations are the same as for
level 1, but they apply when colonoscopy
resources are more limited; Recommendation of
colonoscopy for average-risk male and female at
age 50 to be performed once in a lifetime, in the
absence of factors that would made increased
risk. Recommendations for screening people who
are at high risk are the same as for cascade 1.
• Cascade level 3
The recommendations are the same as for level
1, but they are applied when the colonoscopy
resources are more limited and flexible
sigmoidoscopy are available; recommendation for
screening people at average risk: flexible
sigmoidoscopy for average-risk male and female,
starting at the age of 50 years, every 5 years, in
the absence of factors that would made increased
risk. Diagnostic work-up with colonoscopy when
there is positive sigmoidoscopy; recomendations
for people at high risk are the same as for
cascade 1.
• Cascade level 4
The recommendations are the same as for level
3, but they are applied when the flexible
sigmoidoscopy and colonoscopy resources are
more limited; Recommendation on flexible
sigmoidoscopy for average-risk male and female
is once in a lifetime at the age of 50, in
the absence of factors that would made increased
risk. Diagnostic colonoscopy work-up for
positive sigmoidoscopy or advanced neoplasia
shall be performed depending on the available
colonoscopy resources. Recommendations for
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people at high risk are the same as for cascade1.
• Cascade level 5
The recommendations are the same as for level
4 resources, but they are applied when
the diagnostic colonoscopy is very limited;
flexible sigmoidoscopy is recommended for
average-risk male and female once in a life time
at the age of 50. Diagnostic colonoscopy is
performed only if advanced neoplasia is detected;
recommendation for screening people at high risk
depends on the colonoscopy resources available.
• Cascade level 6
Recommendations are the same as for level 1,
but they can be applied when colonoscopy and
flexible sigmoidoscopy resources are severely
limited; fecal blood testing are recommended
every year for average-risk male and female
starting at the age of 50, in the absence of
factors that would made increased risk. The type
of test used depends on colonoscopy resources
and the dietary habits of the population.
Diagnostic work-up can be performed either with
colonoscopy, if possible, or barium enema (colon
in loop) if the colonoscopy is not available;
Recommendation for screening people at high risk:
the decision to identify separately people for
special screening (level 1) depends on the
available colonoscopy resources. If not available,
those people can have screening as the people at
average risk.
New tests: computed tomographic colonoscopy
(CTC) and fecal DNA testing are available in
a few countries with high/complete resources and
generally not applicable globally; However,
if available, those tests can be offered for male
and female at average risk, starting at the age of
50, who do not wish to be screened by other
more standard method, in order to increase the
people being screening in those countries.
Other colorectal screening that generally
recommended are: fecal testing - fecal occult
blood test, pyruvate kinase type M2 (M2-PK),
K-ras, etc; colon in loop, CT-colonography,
colonoscopy/rectosigmoidoscopy.
Complication
The following complication of CRC may be found,
i.e. lower gastrointestinal tract bleeding through anal
bleeding (hematochezia) with bright red color or
watery stool mixed with blood, anemia, ileus
obstructive, malnutrition and metastases.1,3
INFLAMMATORY BOWEL DISEASE
Type
Inflammatory bowel disease (IBD) is categorized
into ulcerative colitis (UC), Chron’s disease (CD) and
intermediate colitis (the intermediate form of UC and
CD).2,4-7
Etiology/Pathogenesis
The etiology of IBD is still vague until now;
however, there are many predisposition factors that
take role including genetic, antigenic trigger
(pathogenic/non-pathogenic microbacteria, antigenic
food) immune response (autoimmune), antibody
secretion, cytokines, psychological stress.2,4-7
Diagnosis
Diagnosis of IBD is made based on clinical
manifestation collected by history taking, physical
examination, supporting laboratory tests such as
routine laboratory test, colon in loop or colonoscopy
and histopathological examination. On history taking,
we usually find chronic bleeding diarrhea, weight loss,
fever, abdominal pain, extra-intestinal manifestation
(tender joints, apthae). On physical examination, we
may get abdominal pain on palpation, arthralgia,
stomatitis, skin disorder (gangrenous pioderma,
perianal fistulas, etc). There are no characteristic
findings on laboratory tests but reduced hemoglobin
(anemia) may be found, as well as increased
C-reactive protein (CRP) level and positive anti
Saccharomyces cerevisiae antibodies (ASCA), anti
neutrophil cytoplasmic antibodies (ANCA) and
nucleotide oligomerisation domain (NOD) serum level
in some patients. Fecal testing may reveal blood or
positive FOBT. In patients with Crohn disease, the
colon in loop or barium enema examination would
indicate the stricture, fistula, and cobble stone
appearance in ascending colon; while in ulcerative
colitis, the colon in loop or barium enema would reveal
the color button appearances and rectosigmoid
ulceration. On colonoscopy, the following
abnor-malities will be found, i.e. ulceration with/
without skip lesion, pseudopolyp (located on
rectosigmoid indicating ulcerative colitis; when it is
found on ascending colon/ileocaecal, it suggests Crohn’s
disease), granuloma, etc. Histopathological
examination will reveal abnormalities such as crypti
abscess, increased number of basal inflammatory cells,
granuloma, Langhan’s giant cell without caseous
process, etc.2,4-7
Complication
Complication of IBD that can be found include
lower gastrointestinal tract bleeding through anal
bleeding (hematochezia), chronic watery stool mixed
with blood (chronic bleeding diarrhea), anemia,
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stricture, perforation, fistulas and malnutrition. 2,4-7
FECAL OCCULT BLOOD TEST
Fecal occult blood (FOB) is a term for blood present
in stool (feces) that is not visibly apparent by
the naked eyes, but it shall be found by certain tests.
Fecal occult blood test (FOBT) is a test for hidden
(occult) blood in the stool. Conventional FOB looks
for heme; while newer FOBT such as the FIT, look
for globin in the stool. FOB and transferrin rapid test
is a test that looks for hidden (occult) blood in the stool
by checking the presence of globin and transferrin.
The tests can detect 200 ng globin/mL feces and
40 ng transferrin/mL feces. It is considered normal
when only 0.5-1.5 mL of blood a day that escapes
from the blood vessel into the stool each day.
There are several types of FOBT, but the most
common include the three methods,8-18 which are: (1)
The guaiac-based fecal occult blood test to detect
minimal blood loss of at least 10 mL/day (+ 2 tea-
spoons); (2) Fecal immunochemical test (FIT) to
detect blood loss at least 0.3 mL/day, it could detect
blood of 50-200 ng/mL. The test does not detect blood
form the stomach and proximal small intestine, so it is
more specific for bleeding from the colon or lower
gastrointestinal tract; (3) FOB and transferrin rapid
test OT 102c & OT 103c, which is more sensitive and
specific in looking for gastrointestinal bleeding rapidly.
The test can detect at least 200 ng globin/mL feces
and 40 ng transferrin/mL feces.
The blood detection in FOBT involves smearing
some feces onto some absorbent paper or cloth which
has been treated with a chemical substance.
Afterward, a special chemical substance is dropped
onto the stool specimens. If the paper has changed
into blue color, it means that blood is present in
the stool specimens. FOBT may show positive results
in some diseases, such as CRC, hemorrhoid, anal
fissures, colon polyp, inflammatory bowel disease
(ulcerative colitis; Crohn’s disease), gastric cancer,
peptic ulcer, gastroesophageal reflux disease (GERD),
aspirin or nonsteroidal antiinflammatory drugs
(NSAIDs) treatment.
The traditional guaiac-based FOBT test has some
disadvantage that it can be affected by some
substances of food content. Therefore, some foods
should be avoided in several days prior to
the traditional FOBT test. Consuming red meat
(the blood it contains can turn the test positive),
radishes, turnips, cabbage, cauliflower, uncooked
broccoli, horseradish and cantaloupe will cause false-
positive results; while consumption of citrus fruits and
vitamin C supplements can turn the test into false-
negative result.
There are several methods of FOBT:8-18
(1) Traditional method: stool guaiac hemoccult or
instaccult seracult, coloscreen-detects heme; (2) New
test: flushable reagent pads: EZ DetectT, ColoCARE;
(3) Fecal porphyrin quantification: hemoquant – have
a high false-positive result; (4) Immunochemical FOBT:
HemeSelect, QuickVue iFOB, FOBGold or Automated
SENTiFOB or OC Auto 80-Automated iFOBT – more
specific in detecting globin in stool rather than heme.
More sensitive and specific for lower gastrointestinal
tract bleeding; (5) Fecal DNA tests: Pre-Gen-Plus is
a more sensitive test than FOBT and FIT. One study
found that the test is more sensitive than FOBT
(51.6% vs. 12.9%); (6) FOB and transferrin rapid test:
OT-103c/Oncoprobe® – detects globin and transferrin
in stool, more sensitive and specific than guaiac based
FOBT and immune chemical FOBT.
Sensitivity and specificity of FOBT, FIT and FOB +
transferrin rapid
The sensitivity of single FOBT has been found at
30-60%, but if three tests are performed directly (as
in standard) and being used every 1-2 years, the
sensitivity rises to 90-92%.11-13 Sensitivity and
specificity of FIT in detecting CRC are 81.8% and
96.9%, respectively. Moreover, the sensitivity and
specificity of FIT in detecting advanced colorectal
adenoma (non-malignant tumor) are 29.5% and 97.3%,
respectively.15
Transferrin (Tf) has higher significant positiveness
in CRC and pre-malignant lesion (76% Tf vs 61%
immunochemical FOBT (IFOBT), p < 0.05).
Combination of Tf and IFOBT had 90% positive rate
in cancer patients, 78% in premalignant patients, and
29% in low-risk subject. The overall accuracy of
IFOBT and Tf tests for detecting CRC and
pre-malignant lesion are 69.0% and 76.4%.14
Lower gastrointestinal bleeding (hematochezia) can
occur1,2,10,11 as gross bleeding (obvious and massive
bleeding); occult (invisible, small amount); and obscure
bleeding (unidentified bleeding source by regular
endoscopy). Gross and obscure bleeding is apparently
visible by the eyes, and therefore, FOBT is not
necessary. In contrast, FOBT is extremely needed in
occult bleeding to detect any bleeding occur. Obscure
bleeding, which sometimes in the form of occult
bleeding may not be readily visible by the eyes; thus,
FOBT also necessary in this case.
CONCLUSION
FOBT, FIT, FOB and transferrin rapid test are tests
to look for any blood in the stool which are used for
screening of CRC and IBD. FIT and FOB +
transferrin rapid test are tests with the highest
sensitivity and specificity.
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